LOGIN  |  REGISTER
Recursion
Chimerix

Certara to Participate in Upcoming Investor Conferences

May 03, 2022 | Last Trade: US$11.88 0.26 2.24

Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that Company management will participate in the following investor conferences:

  • Bank of America 2022 Healthcare Conference
    Date and Time: Tuesday, May 10 at 3:00 p.m. ET
  • Citi’s Biopharma Virtual Co-Panel Day
    Date and Time: Wednesday, May 18 at 10:00 a.m. ET
  • Jefferies Healthcare Conference
    Date and Time: Wednesday, June 8 – Friday, June 10
    Details to be posted to the Company’s IR website
  • William Blair 42nd Annual Growth Stock Conference
    Date and Time: Thursday, June 9 at 10:20 a.m. ET

Live webcasts for each of the conferences will be available on Certara’s investor relations website at https://ir.certara.com and will be available for replay for at least 90 days thereafter.

About Certara

Certara accelerates medicines using proprietary biosimulation software, technology and services to transform traditional drug discovery and development. Its clients include more than 2,000 biopharmaceutical companies, academic institutions and regulatory agencies across 62 countries.

Investor Relations Contact:
David Deuchler
Gilmartin Group
This email address is being protected from spambots. You need JavaScript enabled to view it.

Media Contact:
Daniel Yunger
Kekst CNC
This email address is being protected from spambots. You need JavaScript enabled to view it.

Stock Quote

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

End of content

No more pages to load

Next page